A shipment of the Sputnik V vaccine
in Buenos Aires, Argentina, May 2021.
A single dose of the pioneering Russian-made Sputnik V vaccine
better protects the elderly against serious Covid-19 infections than
a similar regime of certain other leading vaccines, a major new
of the first component of Gam-COVID-Vac -Sputnik V- on reduction of
Argentina has shown.
The findings were published online by the
EClinicalMedicine, which is run
by the British peer-reviewed medical journal The Lancet.
A team of researchers from Argentina analyzed the data of people who
self-registered on the online vaccination system of the Buenos Aires
Province between December 29, 2020 and March 21, 2021.
Overall, they looked at
nearly 416,000 people who received a first dose of Sputnik V,
including around 40,400 people aged 60-79, who were compared to
39,000 unvaccinated Argentineans.
The research showed that the vaccine was 78.6% effective at
preventing Covid-19 infections, 87.6% effective at reducing
hospitalizations and 84.8% effective at preventing deaths of people
The vaccine's efficacy
was consistent across all other groups, the team said.
For comparison, the scientists summarized eight different studies on
...vaccines that included
people who received one dose.
effectiveness of these four vaccines in preventing symptomatic
infection, hospitalizations and deaths ranged from,
Earlier this year, Russia registered Sputnik Light, a
single-shot vaccine that is essentially the first component of
Sputnik V, which is administered in two shots.
The first doses of
Sputnik V arrived in Argentina in December 2020.
According to Argentina's Health Ministry figures, the country has
received some 9.7 million doses of Sputnik V's first shot from
Russia, as well as over 3.3 million doses of the second.
While deliveries from
Russia continue, Argentina,
has also been
producing Sputnik V at home...
Local production was
launched by the Russian Direct Investment Fund (RDIF),
the agency that bankrolled the vaccine's development, as well as by
Argentinean drug maker
Laboratorios Richmond SACIF
earlier this year.
So far, the company has
produced a total of 2.5 million Sputnik V shots - both first and
second doses - intended for the domestic market.